Director of process development and manufacturing at Pharmaron, Paul Quigley brings more than 30 years of experience in the pharmaceutical and chemical industries to his role. Since joining the business in May 2024, his focus has been on strengthening UK process development and manufacturing operations, building capable teams and supporting growth within Pharmaron’s global network.
Founded in 2004, Pharmaron is a global contract research, development and manufacturing organisation supporting the life sciences sector from drug discovery through to commercialisation.
Paul’s career has consistently centred on pharmaceutical process development and manufacturing leadership. A chemistry graduate and PhD from University College Dublin, later complemented by an MBA from Warwick Business School, he has held senior roles across international organisations, building technical capability, leading multi-site operations and driving business growth.
“What first drew me to the pharmaceutical industry was a genuine interest in organic chemistry and the practical application of science,” Paul explains. “What’s kept me here is the impact, knowing that strong process development and manufacturing underpin the delivery of medicines that change lives.”
For Paul, collaboration is fundamental to that success. As a long-standing member of NEPIC, he sees the cluster as a vital platform for collaborating between industries.
“The pharmaceutical industry has specific technical and regulatory demands and being part of NEPIC gives us visibility within the wider process sector while ensuring our voice is heard,” he says. “It’s not just about networking, it’s about building trusted relationships across the supply chain, sharing common challenges and working collectively to raise the profile of pharmaceutical manufacturing in the North East.”
Collaboration through NEPIC also supports recruitment and skills development. By maintaining close links with universities and other member organisations, Pharmaron can attract emerging talent into the sector and showcase the breadth of opportunity available within pharmaceutical development and manufacturing.
“Operating as a cluster makes us stronger,” Paul adds. “When we collaborate, whether that’s sharing expertise, building partnerships or engaging with government as a collective voice, we create an environment where pharmaceutical businesses can grow and thrive.”